Analytical Data
-
基因名
BDNF
- Application
-
别名
BdnfBrain-derived neurotrophic factor; BDNF) [Cleaved into: BDNF precursor form; ProBDNF)]
-
种属
Human
-
表达系统
E. coli
-
标签
N- Myc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P23560
-
表达区间
19-247aa
-
蛋白长度
Partial
-
分子量
25.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Brain-derived neurotrophic factor (BDNF) is a crucial neurotrophic protein that plays a significant role in neuronal survival, differentiation, and synaptic plasticity, making it essential for cognitive function and mental health. Abnormalities in BDNF signaling are implicated in various neurological and psychiatric disorders, including depression, schizophrenia, and neurodegenerative diseases like Alzheimer's. Given its vital functions, BDNF has become a focal point in biomedical research, particularly regarding its therapeutic potential. The exploration of BDNF recombinant proteins has gained momentum as researchers aim to harness its beneficial effects in treating conditions characterized by neurotrophic deficits. The ability to produce recombinant BDNF allows for the study of its properties in vitro and in vivo, providing valuable insights into its mechanisms of action and potential applications in therapy. Various expression systems, such as bacteria, yeast, and mammalian cells, have been employed to produce functional BDNF. However, challenges remain in ensuring proper folding, post-translational modifications, and bioactivity of the recombinant protein. Understanding these aspects can help optimize BDNF-based therapies and develop novel strategies for promoting brain health and recovery in individuals suffering from neurological impairments. As the field advances, ongoing research into the production, delivery, and efficacy of BDNF recombinant proteins holds promise for unlocking new avenues for treating a range of neurodevelopmental and neurodegenerative disorders.
